Publication Date:
2020
Short description:
Is hyperprogressive disease a specific phenomenom of immunotherapy? / Brambilla, Marta; Lo Russo, Giuseppe; Ferrara, R; Manglaviti, Sara; Garassino, Marina; Occhipinti, Mario. - In: EXPLORATION OF TARGETED ANTI-TUMOR THERAPY. - ISSN 2692-3114. - 9:5(2020), pp. 1143-1161. [10.37349/etat.2020.00027]
abstract:
Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in nonsmall cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments. Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments.
Iris type:
1.1.3. Articolo in Rivista - Editorial, Comment, Reply
List of contributors:
Brambilla, Marta; Lo Russo, Giuseppe; Ferrara, R; Manglaviti, Sara; Garassino, Marina; Occhipinti, Mario
Published in: